迪瑞医疗：10月24日召开董事会会议

Group 1 - The core point of the article is that Dirui Medical (SZ 300396) held a temporary board meeting on October 24, 2025, to discuss the adjustment of the audit committee members [1] - For the first half of 2025, Dirui Medical's revenue composition was 99.37% from medical devices and 0.63% from other businesses [1] - As of the time of reporting, Dirui Medical's market capitalization was 3.8 billion yuan [1] Group 2 - The article also highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine [1] - There is a contrast noted between the thriving secondary market and the cooling fundraising environment in the primary market for biomedicine [1]